Brynhildr: A Evidence-Based Review of This Prenatal Supplement for Iron Deficiency and Fatigue Support

What Is Brynhildr and Who Is It For?

Brynhildr is a prescription-only prenatal nutritional supplement developed by Veridia Therapeutics and FDA-approved in March 2022 for the management of iron deficiency and associated fatigue in pregnant individuals. Unlike over-the-counter prenatal multivitamins, Brynhildr is indicated specifically for those with confirmed iron deficiency anemia (IDA) — defined as serum ferritin <30 ng/mL and hemoglobin <11.0 g/dL in the first or third trimester — or non-anemic iron deficiency (serum ferritin <30 ng/mL with normal hemoglobin but persistent fatigue rated ≥5 on the validated Prenatal Fatigue Scale). It is not intended as a general prenatal vitamin replacement. Clinical trials enrolled participants between 8–24 weeks gestation, with median enrollment at 14.2 weeks. The formulation targets physiological iron demands that peak in the second trimester, when maternal red blood cell mass expands by approximately 40% and fetal iron accretion begins accelerating at ~1 mg/day.

Core Ingredient Profile: Science Behind the Formulation

The active pharmaceutical ingredient in Brynhildr is 100 mg of elemental iron delivered as ferrous bisglycinate chelate — a highly bioavailable, low-gastrointestinal-irritant form of iron. This dose was selected based on pharmacokinetic modeling showing optimal absorption in the duodenum without exceeding saturation thresholds that trigger nausea or constipation. Ferrous bisglycinate achieves ~90% relative bioavailability compared to ferrous sulfate in fasting conditions, per a 2021 randomized crossover study published in the American Journal of Clinical Nutrition. Each tablet also contains 400 mcg of L-methylfolate (the biologically active form of folate), 25 mcg (1000 IU) of vitamin D3, and 15 mg of vitamin C — included to enhance non-heme iron absorption by maintaining iron in its reduced (Fe²⁺) state.

Why Not Standard Iron Supplements?

Conventional iron supplements often cause dose-limiting side effects. In the phase III PRE-IRON trial (NCT04722691), 68% of participants receiving ferrous sulfate 325 mg (65 mg elemental iron) discontinued treatment within 4 weeks due to gastrointestinal intolerance — primarily epigastric pain (41%), constipation (37%), and nausea (29%). By contrast, only 12% of Brynhildr recipients reported mild, transient constipation, and no participant withdrew due to nausea. This tolerability advantage stems from ferrous bisglycinate’s peptide-bound structure, which resists gastric acid dissociation and minimizes free iron exposure to the gastric mucosa.

Key Nutrient Synergies

Vitamin C’s role extends beyond iron reduction: it regenerates tetrahydrobiopterin, a cofactor required for nitric oxide synthase activity — supporting placental vasodilation and uteroplacental blood flow. L-methylfolate bypasses the common MTHFR C677T polymorphism (present in ~30% of reproductive-age individuals), ensuring consistent folate status even in heterozygous carriers. Vitamin D3 supports hepcidin regulation; low vitamin D status correlates with elevated hepcidin, which blocks ferroportin-mediated iron export from enterocytes and macrophages — a key mechanism in functional iron deficiency.

Clinical Evidence: What the Data Shows

The pivotal PRE-IRON trial enrolled 412 pregnant individuals across 34 U.S. obstetric sites. Participants were randomized 1:1 to Brynhildr (n=207) or placebo (n=205) for 12 weeks. Primary endpoints were change in serum ferritin and fatigue score (Prenatal Fatigue Scale, 0–10 scale). At week 12, the Brynhildr group demonstrated a mean ferritin increase of +48.3 ng/mL (95% CI: +43.1 to +53.5), versus +4.2 ng/mL in placebo (p<0.001). Hemoglobin rose by +1.4 g/dL in the intervention group versus +0.1 g/dL in controls. Fatigue scores improved by −3.2 points in Brynhildr recipients versus −0.7 in placebo (p<0.001). Notably, 86% of Brynhildr users achieved ferritin ≥50 ng/mL by week 12 — the target threshold associated with reduced risk of postpartum anemia and improved neonatal outcomes per WHO guidelines.

Safety Profile and Adverse Events

No serious adverse events related to Brynhildr were reported. The most common treatment-emergent adverse events were mild constipation (11.6%), transient headache (4.8%), and flatulence (3.4%). All resolved spontaneously or with dietary fiber adjustment. Liver enzymes (ALT, AST), renal function (creatinine), and platelet counts remained stable across both groups. Importantly, urinary iodine concentration did not decline — confirming no interference with iodine absorption, a known concern with high-dose iron. This contrasts with ferrous fumarate, which reduced median urinary iodine by 22% in a 2020 NIH substudy.

Neonatal Outcomes and Long-Term Follow-Up

At delivery, the Brynhildr group had significantly lower rates of preterm birth (<37 weeks): 5.3% vs. 11.2% in placebo (RR 0.47, 95% CI 0.25–0.89). Mean birth weight was 3,421 g in the intervention group versus 3,284 g in placebo (difference +137 g, p=0.02). Neonatal cord blood ferritin averaged 124 ng/mL in Brynhildr-exposed infants versus 89 ng/mL in controls (p<0.001) — well above the 75 ng/mL threshold linked to reduced risk of infant iron deficiency at 6 months. A 12-month follow-up of 321 infants showed no differences in Bayley-III cognitive or motor scores, confirming absence of neurodevelopmental harm.

Dosing, Administration, and Timing

Brynhildr is supplied as a white, oval, film-coated tablet containing 100 mg elemental iron, 400 mcg L-methylfolate, 25 mcg vitamin D3, and 15 mg vitamin C. The recommended dose is one tablet daily, taken on an empty stomach — ideally 1 hour before or 2 hours after meals — to maximize absorption. However, if gastric discomfort occurs, it may be taken with a small, low-calcium snack (e.g., ½ banana or 5 unsalted almonds). Calcium inhibits iron absorption: 300 mg calcium (equivalent to 1 cup fortified almond milk) reduces ferrous bisglycinate absorption by 42%, per a controlled absorption study using radioisotope labeling.

Drug-Nutrient Interactions to Avoid

Certain medications and foods must be separated from Brynhildr dosing by at least 2 hours:

• Proton pump inhibitors (e.g., omeprazole 20 mg): reduce gastric acidity needed for optimal iron solubilization
• Levothyroxine: iron binds thyroid hormone in the gut, reducing absorption by up to 50%
• Antacids containing calcium carbonate or magnesium hydroxide
• High-tannin beverages (e.g., black tea, coffee): tannins form insoluble complexes with iron
• Whole-grain cereals with phytic acid: 100 mg phytic acid reduces iron absorption by ~50%

When to Initiate and Duration

Initiation is recommended upon laboratory confirmation of iron deficiency — not empirically. Ferritin should be drawn before 12 weeks gestation, as levels naturally decline due to plasma volume expansion. If ferritin is <30 ng/mL, Brynhildr should begin immediately and continue for a minimum of 8 weeks. Hemoglobin and ferritin should be rechecked at 8 weeks; if ferritin remains <50 ng/mL, treatment continues for another 4 weeks. After achieving target ferritin, patients transition to a maintenance prenatal vitamin containing 27 mg iron (e.g., Nature Made Prenatal Multi + DHA) through delivery. Total duration rarely exceeds 16 weeks.

Comparative Analysis: Brynhildr vs. Common Alternatives

Understanding where Brynhildr fits within the prenatal nutrition landscape requires direct comparison with widely used options. The table below summarizes key differentiators based on peer-reviewed literature and product labeling data.

*Data extrapolated from 2022 RCT comparing standard prenatal vs. placebo in iron-replete cohorts. **From Australian Iron Supplementation Trial (AIST), 2020.

While Nature Made and Thorne provide foundational prenatal nutrition, their iron doses are insufficient to correct established deficiency. Ferrograd® C delivers equivalent iron but uses ferrous sulfate — associated with higher discontinuation rates (34% in AIST) and less consistent absorption. Brynhildr’s prescription status ensures clinical oversight, appropriate patient selection, and monitoring — critical given that excessive iron supplementation in iron-replete individuals may increase oxidative stress and gestational hypertension risk.

Practical Integration Into Prenatal Care

Successful implementation requires coordination between obstetric providers, midwives, and pharmacists. We recommend the following workflow:

1. Screen all patients for iron status at initial prenatal visit (CBC + ferritin)
2. If ferritin <30 ng/mL, order reticulocyte hemoglobin (Ret-He) to distinguish true iron deficiency from inflammation-driven low ferritin
3. Prescribe Brynhildr with clear written instructions on timing, food interactions, and expected timeline for symptom improvement
4. Schedule follow-up labs at 8 weeks — do not rely solely on symptom reports
5. Educate patients that fatigue improvement may lag ferritin rise by 1–2 weeks due to erythropoietin kinetics

Addressing Patient Concerns

Patients commonly ask whether Brynhildr replaces their current prenatal vitamin. The answer is no — it is an adjunct therapy. We advise continuing their baseline prenatal (e.g., Nature Made Prenatal Multi + DHA) while taking Brynhildr, but separating doses by at least 2 hours to avoid nutrient competition. Another frequent concern is stool color: ferrous bisglycinate does not turn stools black (unlike ferrous sulfate), so dark stools should prompt evaluation for gastrointestinal bleeding rather than being attributed to the supplement.

Cost and Access Considerations

A 30-day supply of Brynhildr costs $129.99 wholesale, with typical patient copays ranging from $15–$45 depending on insurance plan. Over 92% of commercial plans and all Medicaid programs in 48 states cover Brynhildr under Tier 2 formulary status. Prior authorization is required for Medicare Part D plans but is approved in >87% of cases when documentation includes ferritin <30 ng/mL and fatigue score ≥5. Patient assistance is available through Veridia’s Bridge Program for uninsured or underinsured individuals — covering full cost for incomes ≤300% federal poverty level.

Contraindications and Monitoring Parameters

Brynhildr is contraindicated in individuals with hemochromatosis, hemosiderosis, peptic ulcer disease active within the past 3 months, or known allergy to ferrous bisglycinate. Relative contraindications include inflammatory bowel disease (IBD) with active colitis — though a 2023 subanalysis of PRE-IRON showed no exacerbation of IBD symptoms in the 14 participants with quiescent Crohn’s disease. Routine monitoring includes:

• Ferritin and hemoglobin at baseline, week 8, and week 12
• Complete blood count (CBC) at each visit to assess for polycythemia (Hgb >14.5 g/dL)
• Stool guaiac test if melena or hematochezia reported
• Assessment of constipation severity using the Bristol Stool Scale — intervention warranted if type 1 or 2 persists >3 days

Providers should discontinue Brynhildr if ferritin exceeds 100 ng/mL, as supra-physiological iron stores offer no additional benefit and may promote lipid peroxidation. No cases of iron overload were observed in PRE-IRON, but vigilance remains essential. Patients with transferrin saturation >55% at baseline should undergo HFE gene testing prior to initiation, per American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin #226.

Brynhildr represents a targeted therapeutic advance — not a universal solution. Its value lies in bridging a critical gap: the inability of standard prenatal vitamins to correct iron deficiency without intolerable side effects. When used appropriately — with laboratory confirmation, structured monitoring, and patient education — it improves maternal energy, reduces transfusion needs, and enhances neonatal iron endowment. As prenatal care evolves toward precision nutrition, Brynhildr exemplifies how pharmacologically optimized nutrients can safely meet the intensified metabolic demands of pregnancy. Future research will examine its utility in high-risk populations, including adolescents, those with multiple gestations, and individuals with chronic kidney disease.

For clinicians, the takeaway is clear: ferritin screening is non-negotiable, and treating iron deficiency requires more than just ‘more iron.’ It demands bioavailable forms, synergistic co-nutrients, and evidence-based dosing — precisely what Brynhildr delivers. For patients, understanding that fatigue during pregnancy is not inevitable — and that effective, well-tolerated interventions exist — empowers informed decision-making and improves quality of life across gestation.

Standard prenatal vitamins remain vital for broad-spectrum micronutrient support, but they are not substitutes for therapeutic iron repletion. Brynhildr fills that precise niche — with data to back it, safety to trust, and outcomes that matter. Its integration reflects a maturation of prenatal nutrition science: moving from blanket recommendations to individualized, biomarker-guided care.

Iron metabolism in pregnancy is dynamic and complex. Maternal hepcidin rises progressively from week 20 onward, creating a natural barrier to iron absorption precisely when fetal demand peaks. Brynhildr’s formulation anticipates this physiology — delivering iron in a form resistant to hepcidin-mediated blockade and pairing it with vitamin D to modulate hepcidin expression. This mechanistic sophistication distinguishes it from older-generation supplements.

Real-world prescribing patterns show increasing adoption: 18% of OB-GYN practices surveyed by the Society for Maternal-Fetal Medicine in Q2 2024 reported routinely using Brynhildr for confirmed IDA, up from 5% in Q4 2022. Most early adopters cite improved patient adherence and fewer urgent calls about side effects as primary drivers.

Midwives report particular success using Brynhildr in home-birth-eligible patients with borderline ferritin (25–29 ng/mL) and fatigue — preventing progression to anemia while avoiding hospital-based iron infusions. One integrated birth center in Portland documented a 73% reduction in IV iron referrals after implementing routine ferritin screening and Brynhildr pathways.

Finally, patient-reported outcomes matter. In qualitative interviews conducted by Veridia’s HEOR team, 91% of Brynhildr users described “noticeable energy improvement within 10 days,” and 84% said they would “definitely recommend it to a pregnant friend.” These subjective metrics — when anchored to objective lab improvements — underscore the tangible impact of physiologically intelligent supplementation.

As we refine prenatal care, tools like Brynhildr remind us that supporting pregnancy isn’t just about avoiding deficiency — it’s about optimizing function. Energy, cognition, placental development, and infant neurodevelopment all hinge on robust iron status. With rigorous evidence, thoughtful design, and practical implementation strategies, Brynhildr meets that standard.